BioCryst Pharmaceuticals (BCRX) reported quarterly earnings results on Thursday, Aug-4-2016. The company said it had a profit of $-0.22 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.04. Analysts had a consensus of $-0.26. The company posted revenue of $4.80 million in the period, compared to analysts expectations of $4.33 million. The company’s revenue was down -81.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.06 EPS.
BioCryst Pharmaceuticals opened for trading at $3.69 and hit $3.83 on the upside on Tusday, eventually ending the session at $3.77, with a gain of 1.89% or 0.07 points. The heightened volatility saw the trading volume jump to 7,57,383 shares. Company has a market cap of $278 M.
In a different news, on Dec 22, 2015, Thomas R Ii Staab (Senior Vice President and CFO) sold 3,052 shares at $10.86 per share price. According to the SEC, on Jun 22, 2015, William P Sheridan (Senior VP – CMO) sold 70,389 shares at $15.05 per share price. On Jun 22, 2015, Alane P Barnes (VP, General Counsel & Corp Sec) sold 3,000 shares at $15.00 per share price, according to the Form-4 filing with the securities and exchange commission.
BioCryst Pharmaceuticals Inc. (BioCryst) is a biotechnology company. The Company designs optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment rare diseases. The Company uses X-ray crystallography computer modeling of molecular structures and advanced chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. Its products include RAPIVAB BCX4161 BCX7353 and other second generation HAE compounds BCX4430 and Forodesine. Peramivir is an intravenous neuraminidase inhibitor approved in multiple countries for the treatment of patients with influenza in the United States as RAPIVAB in Japan as RAPIACTA and in Korea as PERAMIFLU. BCX4161 is the Companys Hereditary Angioedema (HAE) product candidate. BCX7353 is a plasma kallikrein inhibitor. Forodesine is a Purine Nucleoside Phosphorylase (PNP) inhibitor.